Customers need to move fast, reduce risk, and build for future commercial success. Our integrated solutions for viral vector help them to reduce complexity and risk within their value chain by leveraging a single vender from raw materials through drug product manufacturing and distribution. We have the technical expertise and support systems (regulatory, analytical development, etc.) to get their product to the clinic seamlessly.
At the Viral Vector Process Development Summit in Boston, we have several opportunities to meet and hear from our experts. Viral Vector subject matter expert, Pouria Motevalian, our Director Process Development will present Process Development and Scale Up of rAVVs Processes: Opportunities for Acceleration and Cost Reduction on Thursday, February 2 at 9:30 am.
Samira Shore, our Director, Technical Program Design will be presenting a poster titled Accelerating path to clinic through an end-to-end solution focused on supply chain, regulatory, and a robust manufacturing process for AAV & LV viral vectors.
You’re invited to a “Meet the Experts” Reception at Ruth’s Chris Steakhouse on Wednesday, February 1 at 5:30 pm. Engage with site leaders from our Plainville, MA site while enjoying cocktails and hors d'oeuvres. Limited space is available so RSVP ASAP.
Register for the tour on Thursday, February 2 at 5:30 p.m. (you will need to make your own arrangements for transportation).
Location: Omni Parker House, 60 School St, Boston, MA
Date and time: January 31-February 2, 2023
Be sure to stop by the Thermo Fisher Scientific booth to chat with us about our Viral Vector services. In the meantime, learn more here.
Director of Process Development,
Thermo Fisher Scientific
As Director of Process Development, Pouria Motevalian leads process characterization, optimization and scale up for viral vectors at Thermo Fisher Scientific. Additionally, he oversees process modeling/simulation and knowledge management activities. Prior to joining Thermo Fisher Scientific, Pouria led early and late-stage process development of biologics, conjugate/mRNA vaccines, at Pfizer. Furthermore, he played an integral part in deploying new technologies focused on digital enablement in bioprocess research and development.
Pouria received his Ph.D. in Chemical Engineering with minor in Computational Science from the Pennsylvania State University. He has been an active contributor to the professional and scientific community in ACS, AIChE and AAPS.